NASDAQ:BIIB
Biogen Inc.
Biogen Inc.'s revenue grew 2.2% in fiscal 2025 to $9.9B. Free cash flow was $2.1B, 20.7% of revenue, and the diluted share count rose 0.8%.Summary generated from Biogen Inc.'s SEC filings. Latest annual report filed Feb 6, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$9.9B
Revenue growth+2.2%
Revenue, 5-yr CAGR−6.0%
Gross margin75.7%
Operating marginn/a
Net margin13.1%
ROICn/a
Return on equity7.4%
Debt / equity0.34
Free cash flow$2.1B
FCF margin20.7%
Share count change+0.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 |
| Operating income | 2,841 | n/a | n/a | n/a | n/a |
| Net income | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 |
| Free cash flow | 3,382 | 1,144 | 1,270 | 2,722 | 2,051 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 1, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 8-K/AAmended current report
Jun 10, 2026 - 8-KEntry into a material agreement
May 14, 2026